Sangamo BioSciences | SGMO - Trade Creditors


Sangamo BioSciences reported $10.74M in Trade Creditors for its fiscal quarter ending in June of 2025.





Trade Creditors Change Date
Alaunos Therapeutics USD 400K 213K Mar/2026
Alnylam Pharmaceuticals USD 126.63M 10.91M Mar/2026
Alterity Therapeutics Limited AUD 1.07M 203.72K Dec/2025
Amgen USD 19.52B 1.37B Mar/2026
Bayer EUR 6.59B 496M Mar/2026
BioCryst Pharmaceuticals USD 10.96M 4.87M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Cipla INR 32.3B 1.95B Mar/2026
Clal Biotechnology ILS 21.05M 1.62M Dec/2021
Compugen USD 2.35M 6.77M Dec/2025
CSL USD 3.17B 290M Dec/2025
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Grifols EUR 987.75M 47.87M Dec/2025
Ionis Pharmaceuticals USD 26.03M 2.05M Mar/2026
J&J USD 10.46B 1.53B Mar/2026
Karyopharm Therapeutics USD 4M 1.39M Dec/2025
Merck USD 3.86B 541M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Omeros USD 8.84M 4.42M Jun/2025
Pfizer USD 4.51B 734M Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sangamo BioSciences USD 10.74M 7.46M Jun/2025
Sanofi EUR 22.71B 219M Mar/2026
Sarepta Therapeutics USD 70.38M 210.46M Mar/2026
Tectonic Therapeutic USD 2.55M 1.46M Mar/2026
Ultragenyx Pharmaceutical USD 42M 11M Mar/2026
Vertex Pharmaceuticals USD 3.47B 40.6M Mar/2026